Atlas of non-FDG PET--CT in diagnostic oncology.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Vienna : International Atomic Energy Agency, 2021.
Colección:IAEA human health series ; no. 38
Temas:
Tomography, Emission.
Tomography.
Cancer > Radionuclide imaging.
Oncology.
Tomography, Emission-Computed
Medical Oncology
Tomographie par émission.
Tomographie.
Cancer > Scintigraphie.
Cancérologie.
Cancer > Radionuclide imaging
Oncology
Tomography
Tomography, Emission
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • 1. INTRODUCTION
  • 1.1. Background
  • 1.2. Objective
  • 1.3. Scope
  • 1.4. Structure
  • 2. ACETATE (11C)
  • 2.1. General characteristics
  • 2.2. Pharmacokinetics
  • 2.2.1. Physiological biodistribution and metabolism
  • 2.2.2. Mechanism of retention
  • 2.2.3. Pharmacology and toxicology
  • 2.3. Methodology
  • 2.3.1. Activity, administration, dosimetry
  • 2.3.2. Imaging protocol
  • 2.4. Clinical aspects
  • 2.4.1. Indications
  • 3. Bevacizumab (89Zr)
  • 3.1. General characteristics
  • 3.2. Pharmacokinetics
  • 3.2.1. Metabolism
  • 3.2.2. Mechanism of retention
  • 3.2.3. Pharmacology and toxicology
  • 3.3. Methodology
  • 3.3.1. Activity, administration, dosimetry
  • 3.3.2. Imaging protocol
  • 3.4. Clinical aspects
  • 3.4.1. Indications
  • 4. Choline (11C)
  • 4.1. General characteristics
  • 4.2. Pharmacokinetics
  • 4.2.1. Physiological biodistribution and metabolism
  • 4.2.2. Mechanism of retention
  • 4.2.3. Pharmacology and toxicology
  • 4.3. Methodology
  • 4.3.1. Activity, administration, dosimetry
  • 4.3.2. Imaging protocol
  • 4.4. Clinical aspects
  • 4.4.1. Indications
  • 5. Choline (18F)
  • 5.1. General characteristics
  • 5.2. Pharmacokinetics
  • 5.2.1. Physiological biodistribution and metabolism
  • 5.2.2. Mechanism of retention
  • 5.2.3. Pharmacology and toxicology
  • 5.3. Methodology
  • 5.3.1. Activity, administration, dosimetry
  • 5.3.2. Imaging protocol
  • 5.4. Clinical aspects
  • 5.4.1. Indications
  • 6. FLUORO-DIHYDROTESTOSTERONE
  • FDHT (18F)
  • 6.1. General characteristics
  • 6.2. Pharmacokinetics
  • 6.2.1. Physiological biodistribution and metabolism
  • 6.2.2. Mechanism of retention
  • 6.2.3. Pharmacology and toxicology
  • 6.3. Methodology
  • 6.3.1. Activity, administration, dosimetry
  • 6.3.2. Imaging protocol
  • 6.4. Clinical aspects
  • 6.4.1. Indications
  • 7. F-DOPA (18F)
  • 7.1. General characteristics
  • 7.2. Pharmacokinetics
  • 7.2.1. Physiological biodistribution and metabolism
  • 7.2.2. Mechanism of retention
  • 7.3. Methodology
  • 7.3.1. Activity, administration, dosimetry
  • 7.3.2. Imaging protocol
  • 7.4. Clinical aspects
  • 7.4.1. Indications
  • 8. Fluoroestradiol, FES (18F)
  • 8.1. General characteristics
  • 8.2. Pharmacokinetics
  • 8.2.1. Physiological biodistribution and metabolism
  • 8.2.2. Mechanism of retention
  • 8.2.3. Pharmacology and toxicology
  • 8.3. Methodology
  • 8.3.1. Activity, administration, dosimetry
  • 8.3.2. Imaging protocol
  • 8.4. Clinical aspects
  • 8.4.1. Indications
  • 9. Fluoroethyl-tyrosine, FET (18F)
  • 9.1. General characteristics
  • 9.2. Pharmacokinetics
  • 9.2.1. Physiological biodistribution and metabolism
  • 9.2.2. Mechanism of retention
  • 9.2.3. Pharmacology and toxicology
  • 9.3. Methodology
  • 9.3.1. Activity, administration, dosimetry
  • 9.3.2. Imaging protocol
  • 9.4. Clinical aspects
  • 9.4.1. Indications
  • 10. FLUOROTHYMIDINE, FLT (18F)
  • 10.1. General characteristics
  • 10.2. Pharmacokinetics

Ejemplares similares